Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximab.
Shimizu
Masaki
M
Kitagawa
Kiyoki
K
Nishio
Sayaka
S
Yokoyama
Tadafumi
T
Furuichi
Kengo
K
Ohta
Kazuhide
K
Wada
Takashi
T
Yachie
Akihiro
A
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000627:therapeutic use*; D018951:Antigens, CD20; D001706:Biopsy; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005923:Glomerulosclerosis, Focal Segmental / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006084:Graft Rejection / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D007668:Kidney / Q000648:ultrastructure; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D007937:Leukapheresis / Q000379:methods*; D008854:Microscopy, Electron; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D000069283:Rituximab; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab